Caldwell Sutter Capital, Inc. Sellas Life Sciences Group, Inc. Transaction History
Caldwell Sutter Capital, Inc.
- $234 Billion
- Q3 2025
A detailed history of Caldwell Sutter Capital, Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 100 shares of SLS stock, worth $143. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$143
Previous $219,000
26.48%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLS
# of Institutions
100Shares Held
27.8MCall Options Held
3.85MPut Options Held
126K-
Vanguard Group Inc Valley Forge, PA6.84MShares$9.78 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX6.03MShares$8.63 Million1.59% of portfolio
-
Marshall Wace, LLP London, X02.36MShares$3.37 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.26MShares$3.24 Million0.0% of portfolio
-
State Street Corp Boston, MA1.36MShares$1.95 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $29.4M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...